M3 Inc (JP:2413)

:2413

2413

RESEARCH TOOLSreports

Want to see JP:2413 full AI Analyst Report?

M3 (2413) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2413 Analyst Ratings

Moderate Buy

5 Buy

3 Hold

0 Sell

Based on 8 analysts giving stock ratings to

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2413 Stock 12 Month Forecast

Average Price Target

¥2,226.25

▲(3.21% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for M3 in the last 3 months. The average price target is ¥2,226.25 with a high forecast of ¥3,540.00 and a low forecast of ¥1,780.00. The average price target represents a 3.21% change from the last price of ¥2,157.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1495":"¥1,495","2518":"¥2,518","3541":"¥3,541","2006.5":"¥2,006.5","3029.5":"¥3,029.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3540,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥3.54K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2226.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥2.23K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1780,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.78K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1495,2006.5,2518,3029.5,3541],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1496.5,1653.6923076923076,1810.8846153846152,1968.076923076923,2125.2692307692305,2282.461538461538,2439.653846153846,2596.846153846154,2754.0384615384614,2911.230769230769,3068.4230769230767,3225.6153846153848,3382.8076923076924,{"y":3540,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1496.5,1552.6346153846155,1608.7692307692307,1664.9038461538462,1721.0384615384614,1777.173076923077,1833.3076923076924,1889.4423076923076,1945.576923076923,2001.7115384615386,2057.846153846154,2113.9807692307695,2170.1153846153848,{"y":2226.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1496.5,1518.3076923076924,1540.1153846153845,1561.923076923077,1583.7307692307693,1605.5384615384614,1627.3461538461538,1649.1538461538462,1670.9615384615386,1692.7692307692307,1714.576923076923,1736.3846153846152,1758.1923076923076,{"y":1780,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1759.958,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1997.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1901.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1865.575,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2224.871,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2238.197,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2141.463,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2421.793,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2086.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1857.678,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1645.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1669,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1496.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥3,540

Average Price Target¥2,226

Lowest Price Target¥1,780

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

UBS

Not Ranked

UBS

¥2,040

Buy

-5.42%

Downside

Reiterated

05/13/26

UBS Remains a Buy on M3 (MTHRF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥2,100

Buy

-2.64%

Downside

Reiterated

05/07/26

Morgan Stanley Keeps Their Buy Rating on M3 (MTHRF)

Unknown Analyst

Nomura

Not Ranked

Nomura

¥3,540

Buy

64.12%

Upside

Reiterated

05/07/26

Nomura Keeps Their Buy Rating on M3 (MTHRF)

Naoko Saito

J.P. Morgan

¥2,500

Buy

15.90%

Upside

Reiterated

05/01/26

J.P. Morgan Reaffirms Their Buy Rating on M3 (MTHRF)

Akinori Ueda

Goldman Sachs

¥2,300→¥2,050

Hold

-4.96%

Downside

Assigned

04/15/26

Goldman Sachs Remains a Hold on M3 (MTHRF)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

¥1,800

Hold

-16.55%

Downside

Reiterated

03/06/26

Jefferies Sticks to Their Hold Rating for M3 (MTHRF)

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥2,800→¥2,000

Buy

-7.28%

Downside

Reiterated

03/04/26

Daiwa Keeps Their Buy Rating on M3 (MTHRF)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

¥2,600→¥1,780

Hold

-17.48%

Downside

Reiterated

02/17/26

Mizuho Securities Keeps Their Hold Rating on M3 (MTHRF)

Hidemaru Yamaguchi

Citi

¥2,600→¥2,800

Buy

29.81%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), M3 (Other OTC: MTHRF) and Sarepta Therapeutics (NASDAQ: SRPT)

Unknown Analyst

Tokai-Tokyo Securities

Not Ranked

Tokai-Tokyo Securities

¥2,800→¥2,300

Buy

6.63%

Upside

Reiterated

02/06/26

Tokai-Tokyo Securities Reaffirms Their Buy Rating on M3 (MTHRF)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

¥2,600

Buy

20.54%

Upside

Reiterated

01/28/26

Bank of America Securities Sticks to Its Buy Rating for M3 (MTHRF)

Unknown Analyst

SMBC Nikko

Not Ranked

SMBC Nikko

¥2,700

Hold

25.17%

Upside

Reiterated

11/25/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

UBS

Not Ranked

UBS

¥2,040

Buy

-5.42%

Downside

Reiterated

05/13/26

UBS Remains a Buy on M3 (MTHRF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥2,100

Buy

-2.64%

Downside

Reiterated

05/07/26

Morgan Stanley Keeps Their Buy Rating on M3 (MTHRF)

Unknown Analyst

Nomura

Not Ranked

Nomura

¥3,540

Buy

64.12%

Upside

Reiterated

05/07/26

Nomura Keeps Their Buy Rating on M3 (MTHRF)

Naoko Saito

J.P. Morgan

¥2,500

Buy

15.90%

Upside

Reiterated

05/01/26

J.P. Morgan Reaffirms Their Buy Rating on M3 (MTHRF)

Akinori Ueda

Goldman Sachs

¥2,300→¥2,050

Hold

-4.96%

Downside

Assigned

04/15/26

Goldman Sachs Remains a Hold on M3 (MTHRF)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

¥1,800

Hold

-16.55%

Downside

Reiterated

03/06/26

Jefferies Sticks to Their Hold Rating for M3 (MTHRF)

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥2,800→¥2,000

Buy

-7.28%

Downside

Reiterated

03/04/26

Daiwa Keeps Their Buy Rating on M3 (MTHRF)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

¥2,600→¥1,780

Hold

-17.48%

Downside

Reiterated

02/17/26

Mizuho Securities Keeps Their Hold Rating on M3 (MTHRF)

Hidemaru Yamaguchi

Citi

¥2,600→¥2,800

Buy

29.81%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), M3 (Other OTC: MTHRF) and Sarepta Therapeutics (NASDAQ: SRPT)

Unknown Analyst

Tokai-Tokyo Securities

Not Ranked

Tokai-Tokyo Securities

¥2,800→¥2,300

Buy

6.63%

Upside

Reiterated

02/06/26

Tokai-Tokyo Securities Reaffirms Their Buy Rating on M3 (MTHRF)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

¥2,600

Buy

20.54%

Upside

Reiterated

01/28/26

Bank of America Securities Sticks to Its Buy Rating for M3 (MTHRF)

Unknown Analyst

SMBC Nikko

Not Ranked

SMBC Nikko

¥2,700

Hold

25.17%

Upside

Reiterated

11/25/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering M3

3 Months

Kyoichiro ShigemuraNomura

Success Rate

4/9 ratings generated profit

Average Return

+9.70%

Copying Kyoichiro Shigemura's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +9.70% per trade.

1 Year

Kyoichiro ShigemuraNomura

Success Rate

4/9 ratings generated profit

Average Return

-12.01%

Copying Kyoichiro Shigemura's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -12.01% per trade.

2 Years

Kyoichiro ShigemuraNomura

Success Rate

0/9 ratings generated profit

Average Return

-27.53%

Copying Kyoichiro Shigemura's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -27.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2413 Analyst Recommendation Trends

Rating

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2413 has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 2413 average Analyst price target in the past 3 months is 2,226.25.

Each month's total comprises the sum of three months' worth of ratings.

2413 Financial Forecast

2413 Earnings Forecast

Next quarter’s earnings estimate for 2413 is ¥19.83 with a range of ¥18.88 to ¥20.77. The previous quarter’s EPS was ¥11.11. 2413 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2413 has Performed in-line its overall industry.

2413 Sales Forecast

Next quarter’s sales forecast for 2413 is ¥94.95B with a range of ¥93.50B to ¥96.68B. The previous quarter’s sales results were ¥86.97B. 2413 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2413 has Performed in-line its overall industry.

2413 Stock Forecast FAQ

What is JP:2413’s average 12-month price target, according to analysts?

Based on analyst ratings, M3 Inc’s 12-month average price target is 2,226.25.

What is JP:2413’s upside potential, based on the analysts’ average price target?

M3 Inc has 3.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is M3 Inc a Buy, Sell or Hold?

M3 Inc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.

What is M3 Inc’s share price target?

The average share price target for M3 Inc is 2,226.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥3,540.00 ,and the lowest forecast is ¥1,780.00. The average share price target represents 3.21% Increase from the current price of ¥2,157.

What do analysts say about M3 Inc?

M3 Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of M3 Inc?

To buy shares of JP:2413, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

M3 (2413) Stock Forecast & Price Target

2413 Analyst Ratings

2413 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering M3

2413 Analyst Recommendation Trends

2413 Financial Forecast

2413 Earnings Forecast

2413 Sales Forecast

2413 Stock Forecast FAQ

Detailed List of Analyst Forecasts